Therapy strategies for acute coronary syndrome and after coronary interventions. Antiplatelet agents and anticoagulants

• Published in: Der Internist (Berlin) 2011-11, Vol.52 (11), p.1292-1300
• Main Authors: Divchev, D, Nienaber, C, Ince, H
• Format: Article
• Language: ger
• Subjects: Acute Coronary Syndrome - therapy; Anticoagulants - therapeutic use; Europe; Fibrinolytic Agents - therapeutic use; Humans; Internal Medicine - standards; Myocardial Revascularization - adverse effects; Myocardial Revascularization - standards; Practice Guidelines as Topic; Thrombolytic Therapy - standards; Thrombosis - drug therapy; Thrombosis - etiology; Thrombosis - prevention & control
• ISSN: 1432-1289
• DOI: 10.1007/s00108-011-2836-1

There is ongoing development of new therapeutic regimens in the use of antithrombotic agents and anticoagulants focussing on acute coronary syndrome (ACS) with an increasing impact on current guidelines over the last years. This was especially accompanied by an increase in innovative percutaneous coronary interventional (PCI) methods in patients with ACS, non-ST-segment elevation myocardial infarction (NSTEMI) or ST-segment elevation myocardial infarction (STEMI) with a need for therapeutics with more sufficient and effective antiplatelet action. On the other hand, newer direct and indirect thrombin inhibitors with primary use in prevention and therapy of thromboembolic events have been shown to have beneficial and even superior effects in ACS with or without PCI. The current review aims to report on the evidence-based use of approved antithrombotic agents and anticoagulants in ACS with special focus on PCI according to the actualized European guidelines.